Aim: The modified Rodnan skin score (mRSS) is a validated outcome measure for skin thickness in systemic sclerosis (SSc). Training has been shown to reduce variability in the measurement of mRSS. Our objective was to assess the inter-and intra-observer variability of mRSS scoring using the proposed recommendations for training by the and (c) live demonstration of mRSS on one SSc patient. In the evaluation phase, each trainee independently assessed the mRSS in four SSc patients. For intra-observer reliability, 14 trainees re-assessed the mRSS of two SSc patients whom they had previously examined. We computed the inter-and intra-observer variability using a linear mixed model. 
| INTRODUC TI ON
Systemic sclerosis (SSc) is characterized by skin tightening and thickening. Based on the extent of skin involvement, SSc is sub-classified into limited cutaneous SSc (lcSSc) with skin thickening distal to the elbows and knees with or without face involvement, or diffuse cutaneous SSc (dcSSc) with skin thickening proximal as well as distal to the elbows and knees, and can occur with or without involvement of the face. 1 In particular, early in the disease, more extensive skin involvement is associated with more severe internal organ manifestations and poorer prognosis. 2, 3 The modified Rodnan skin score (mRSS) 4 is a validated outcome measure for skin thickness in SSc clinical trials. It is recommended that the same assessor examine the patient for the duration of the trial as each outcome measure inherently has measurement variability. 5 Training assessors has been shown to reduce variability in mRSS assessment. 5 The aim of this study was to assess the effectiveness of a sys- 
| ME THODS
We assessed the inter-and intra-observer variability of mRSS in a group of trainees who participated in the skin score workshop conducted as part of the 18th Singapore Society of Rheumatology-Malaysian Society of Rheumatology pre-congress workshops in Singapore.
| Participants
Two SSc experts (DK, AL) and two facilitators (GC, NSC), 52 train- had lcSSc and four had dcSSc (see Table 1 for their mRSS scores).
| Skin scoring
The mRSS is calculated by summation of measurements of skin thickness in 17 different body sites including the face, upper arms, forearms, dorsum of hands, fingers, chest, abdomen, thighs, legs and feet.
The maximum total score is 51 and each area is graded as follows: 0 = normal skin, 1 = mild skin thickening, 2 = moderate skin thickening with difficulty in making skin folds and no wrinkles, 3 = severe skin thickness with inability to make skin folds between two examining fingers. 5 Trainees were taught that the three commonly used techniques for mRSS skin scoring are that of global average, maximum score and representative area. For purposes of standardization in this workshop, the global average method was used.
| Conduct of the skin scoring workshop
Similar to how other workshops are conducted, (two each for trainees and four each for experts) whom they had examined 2 days ago. The repeat mRSS score for each trainee was compared to their original scores. A score of ≤3 was considered acceptable intra-observer variability, as supported by previous studies with an intra-observer variability of 2.5-2.9. 
| Statistical analysis
We computed the inter-and intra-observer variability using a linear mixed model with an intercept term, a random effect for the patient, a random effect for the scorer, and a random effect for the interaction of patient and scorer, as previously described. The intra-observer variability for the 14 trainees and two experts 2 days later showed an acceptable within-patient SD of 2.56 (see Table 2 ). The test-retest score was within one unit for the experts. The coefficient of variation was 39%.
| D ISCUSS I ON
The mRSS is a feasible, reliable, valid, and responsive measure and is used as a primary or secondary outcome measure in clinical trials. 8 In a Phase 2 trial, 9 mRSS was able to differentiate tocilizumab from placebo. Mycophenolate mofetil and cyclophosphamide were both shown to be superior to placebo in post-hoc analysis of the However, this may result in higher inter-observer variability in the primary outcome measure, the mRSS. One way to reduce this variability is to protocolize the way patients are evaluated to reduce variability between assessors due to subtle differences in assessing the mRSS and also different methods utilized in scoring mRSS (global average vs maximum score vs representative area). The global average and representative area techniques are recommended as they are likely more sensitive to change than the maximum score technique. 5 The intra-observer variability has been shown consistently by various studies to be lower than inter-observer variability. 6, 7, 12 It is therefore recommended that the same assessor evaluates the patient throughout a trial to reduce measurement variability. Training of practitioners in mRSS evaluation will have the effect of reducing the variability and provides a platform to standardize mRSS for a trial. 5 Although the teaching and standardization has been performed in different trials (Dr D.K. Khanna, personal communication), to our knowledge, this is the first study to prospectively incorporate the SCTC/WSF recommendations in a group of general rheumatologists and research coordinators. We determined that training workshops are feasible, and we found good inter-observer reliability and excellent intra-observer reliability for mRSS scoring in a group of trainees who underwent a structured and standardized mRSS workshop. This study is an important contribution to the field as it provides evidence of intra-rater and inter-rater reliability among both physicians and research staff.
The inter-observer SD was noticed to be 4.3 units and was consistent with previous studies 6 (within-patient SD 3.8-8.5), and was well within the recommended SCTC/WSF proposed upper limit of five units. Likewise, the intra-observer within-patient SD was consistent with previously reported figures of 2.5-2.9.
Few studies have been conducted to investigate intra-observer variability of mRSS scoring. We report intra-observer variability on the same group of patients examined 2 days after the initial training session. This would have reduced recall bias compared to the study by Gordon et al, where patients were re-examined on the same day with an intra-observer variability of 0.94. 7 In the studies by Clements et al 12 and Czirjak et al 6 patients were re-examined 2-8 weeks later to quantitate intra-observer variability and the intraobserver within-patient SD was found to be 2.5-2.9.
The coefficient of variation (CV) was on the higher end of the range in our study (39%-56%) compared to other studies (11.8%-54%) 6, 7, 12 despite acceptable within-patient SD for both inter-and intra-observer variability. This could be due to the lower median skin score of five in our patients compared to mean scores of 8.6-20.7 reported in other studies, resulting in a larger CV for minimal variation in SD (since CV is derived from SD divided by the mean).
The lower ICC when experts were included in the analysis for intra-observer variability likely reflected the tendency for most trainees to score higher than the experts, an observation similarly noted in other studies, 6 where skin tethering may erroneously be scored as skin thickness.
Our data shows that 65.4% of the trainees were provided certificates, based on the predefined variability of up to five units. We do not have published data from other studies on proportion of those who passed the evaluation phase but this is likely lower due to the mix of the trainees. In the opinion of the senior author (DK), the proportion is higher in those who perform skin scoring training on a regular basis in clinics or those who have participated in previous clinical trials. To address over-scoring of skin tethering, training workshops can include patients with higher mRSS scores (ie reflective of how patients are enriched for clinical trials) as well as patients with atrophic and tethered skin so as to emphasize their difference, to further improve training.
We believe our results are especially encouraging as the trainees were of a heterogeneous background ranging from experienced rheumatologists to rheumatology trainees to research coordinators with no medical training, many of whom are not scleroderma experts. Further, the findings from our study may be generalized to TA B L E 2 Inter-and intra-observer variability for skin score workshop Our study has several limitations. Ideally the repeat scoring to evaluate intra-observer variability could have been done 2-4 weeks later to further minimize recall bias which may occur within a 2-day interval. This has to be balanced against a longer interval (eg more In summary, this is the first study examining the training of assessors using the SCTC/WSF training recommendations demonstrating good and excellent inter-and intra-observer variability for skin scoring. Standardized training of skin scoring is strongly encouraged to enable reliable mRSS scoring, a key outcome measure in SSc clinical trials.
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